米托蒽醌联合化疗治疗晚期乳腺癌临床观察

目的:观察以米托蒽醌为主的联合化疗治疗晚期乳腺癌的近期疗效与毒性反应.方法:将晚期乳腺癌44例随机分为治疗(CMxF)组23例和对照(CAF)组21例 .结果:治疗组完全缓解(CR)3例,部分缓解(PR)9例,恶化(PD)2例,稳定(S D)9例,有效率52.2%;对照组CR 3例,PR 9例,PD 1例,SD 8例,有效率57.1%;两组疗效差异无显著性(P＞0.05). 毒性反应中消化道反应发生率分别为47.8%和52.4%,差异无显著性(P＞0.05);两组白细胞下降率分别为87.0%和95.2%,差异无显著性(P＞0.05);CAF组ECG异常23.8%,治疗组无ECG异常,心脏毒性差异有显著性(P＜0.05).结论:米托蒽醌联合化疗治疗晚期乳腺癌与阿霉素联合方案比较疗效相当 ,但心脏毒副作用轻.

Mitoxantrone combination chemotherapy for advanced breast cancer

Objective:To evaluate the effect and side effect of mitoxantrone combination chemotherapy for advanced breast cancer.Methods:Forty four cases with advanced breast cancer were randomly divided into CMxF group(23 cases) and CAF group(21 cases).Results:In CMxF group CR achieved in 3,PR in 9,PD in 2,SD in 9,the response rate of CR+PR was 52.2%.In CAF group,CR achieved in 3,PR in 9,PD in 1,SD in 8,the response rate of CR+PR was 57.1%.There was no significant difference in PR between them( P >0.05).As for side effect,the occurence rate of gastrointestinal tract reaction was 47.8% and 52.4%,respectively.There was no significant difference between them( P >0.05).Neutropenia of the two regimens were 87.0% and 95.2 %,respectively.The difference was no significant( P >0.05).The difference in cardiotoxicities was significant( P <0.05).Conclusions:The effect of mitoxantrone combined chemotherapy is satisfactory in treatment of advanced breast cancer and the toxicity is low.